Chanty registration number.. 1189246
Brit-PACT
th Arthriti5 CfAwTknI
BRITISH PSORIATIC ARTHRITIS CONSORTIUM
TRUSTEES. REPORT AND
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
D.R. Hicks
<TEREO

British Psoriatlc Arthrltis Consortium
Contents
Page
Trustees. Report
IndePe￿ent Examiner's Report
Statement of Financial Activitie5
Compardtive St6tement of Financial Activities
Statement of Financial Posltlon
Notes to the ￿nanc￿al Statements
9-12
The following pages do not forni part of the statutory accounts..
Detailed Staternent of Financial Activities
13

British Psoriatic Arthrltls Consortlum
Trustees. Report For The Year Ended 31 March 2026
The trLtstees present thelr report and the finaacial statements for rhe year efjded 31 March 2026.
Objectlves and Actlvltles
Alm$ and Objectlves
"The oblett of the CIO 15 to relieve slckness and to preserve and protect good health for the put￿1£ benefit by promoting
edical knowledge. and excellence through education and ￿SearCh with particular reference to the dlseases of psorlasSs
and psoriatic arthritis.
Public Benefit
In this financlal year. Brit-PACT continued lo progress Yiith its mission to support education and research Into P50riatlc
arthritls IPsA} In the UK.
We held another successful Annual Meeting in the hybrid forrnat at the BCEC. Birmlngham, on 10th October 2025 and it V4as
organised and chaired by Prof Pauline Ho, Dr Muhamad Jaslm and Dr Ashley Elliot. 39 delegates attend￿ the meetlng in
person while another 24 attendees loinÈd in online. The meeting hlghllghts Included a presentstion by Dr Andrea DI Matteo
about the use of ultrasound in p50riatic disease and how thar can help guide treatment declsions. We also 4 debate on
the topk'The use of dual biologic therapy in PSA.. 15 thi5 required?. with Prof Bruce Kirkham speaking for the rnotlon and Dr
WllliatH Tillett aryuing against the motion. Mr Andy Kelly provided an update on bÈhèlf of the Brit-PAcf Patient Partner5 and
that was followed by an onlinè Ease presentation and discussion about the use of dual biologics by Prof Helena Marzo-
Ortega. There were also presentations from BrIt-pA￿ Researcher and Clinician Abstract Prize Wlnner5 and Runners up as
well as updates regardlng the various Brit-PACT funded ￿searCh projects. Excellent feedbèck was received for the meeting
wlth 93% of the attendees rating the meetlng'highly relevant. to their educational needs while o further 4% felt that the
meeting was 'mosily relevant, regarding thi5 objective.
MO￿0￿er. In November 2025 we also had the StM)ndyloarthritis Golden Anniversary Meeting in Leed5. The purpose of It via5
to celebrate and review th& flve decade5 of 5cientiFic dlscovery. dinical progress, and collaborative partnershlps since the
f￿r5t publicatlon on the sptrndyloarthritis ISpAI concept 50 years ago. The rneetlng was jolntly arranged L>y us and Brit-5pA.
our sister oryanlsation which focuses on axial spondyloarthrftls. and wa5 chaired by Professors Philip Helliwell and Helena
Marzo-ortega. This was a 2-day event with 100 attendees and it began on Thursday 27th NOVem￿r ÈvÈning with a warm
and engaging Celebrètion Dinner. Prof Helliwell ènd Prof Marzo Ortega opened the evening ¥Ylth v4elcomin9 remarks and
reflèttions on the history of the SpA contept. This was followed by an excellent talk frotn Prof lain McInnes, who explored
how our understanding of SPA pathophysiology has evolved dramatically over the last 50 years. an(J what the future might
hold for us. The annlversary meeting on Friday 28th November had presenta110ns from an outstandlng Ilne up of national
and internatlonal experts, Èach highlighting key milestones and ernerglng directions in SpA research. The p￿SentationS
covered the evolution of classification criteria, advances In (magingf the role of animal models in shaping scientific
understanding. and tnajor developments in genebC5. Further sessions focused on axial and peripheral disease, the
importance of iecognising skin involvement. the transfomatlon of treatment strategies over time. The meetlng
concluded wlth forward-look￿n9 discu55ions on future initiatives and research opportuniti￿, offer)ng an exciting glimpse of
hat lies ahead. By bringing t￿ether pioneers who shaped the field and innovators who are driving it forward. the Golden
Anniversary Meedng proved to be a memorable celebration of progre55 and an inspiring foundation for the next chapter in
SpA research. UR5urprisingly. excellent feedbark was ￿ceiVed for this meetlng totr with 95% of the attendee5 ratlng the
ffleeting'highly relevafit, to their educational need5 while a further 5% lelt that rhe meetln9 was'mosily relevant. regarding
thi5 objectlve.
The 8rit-PACT pilot research grant scheme continues as before and the award for this is n¢)w in rnemory of Or Oeepak
Jadon. a valued member of the 8rit-PAcf steertng committee. who sadly died ln 2023. All grants submltted were asked to
Inclut3e at least one of the'Top IO, items Identified in the James Lind Priority Setting Partner5hipi which had been funded
and publlshed previously by Brit-PAcf. The applitant5 were also asked to address an issue of importance and relevance to
psoriatic disease and in line with the aims and purposes of Brit-PACT. Four hlgh quality appli¢ation5 were received and one
research grant of £1S.000 was awarded to a researcher at the Universlty of Manchester.
We have also continued to support other research with external funding. The SEQUENCE projert, a multicentre
observational study that was launthed in 2022 to understand Inequity of biologic5 preSCrib￿ng across the UK and had high
engagement from the genÈral 8rit-PAcf membership. has now been eotnpleted. Updates on this study were provided by Dr
Chadotte Gollins at the annual meeting In ottober 2025 and articles based on it have been published in Rheurnatologyi the
flagship loijrnal of the British Society for Rheumatology. The White Swan projett involved using social rnedia data to
understand the lived experience of people ¥vith psoriatic arthritis receiving biologic therapiÈ5 and weight Tnana9ement
interventions. An update abotst this project was also presented by Dr James Kimpton at the annual tneeting in ottober 2025
and an abstract based on the findings was presented as a poster at the 8SR (British Society for Rheumatology) annual
conference In April 2026.
8rit-PACT continues to prtsvide suptK)rt and updates to the B￿tISh Society for Rheumatology on Its actlvlties and provide5
support to subcommittees of the BSR such as recommendatlOn5 for biologic use In pso￿atIC arthritis.
Page I

British Psoriatic Arthritis Consortium
Trustees. Report {continued)
For The Year Ended 31 March 2026
The trustees confirm that they have complied with the requirements of Section 17 of rhe Charitles Art 2011 to have due
regard to the Charity Commisslon's guidance on public benefit.
Achievements and Performanre
Maln Athltsvéménts
l. Psoriatic Arthritls Education for Health Care Professionals
Brit-PAcf continues to conduct educational meetings for rheurnatology health care professiona15 and seeks to grow
membÈrship with a wider spectrum of HCP5, including dermatolo9i5ts and allied health professionals. Our main educational
events this year were the Artnual meeting in October 2025 and the Spondyloarthritis Golden Annlversary Meeting In
November 2025. An update on behalf of the Charity was also presented as part of the Spondyloarthfitls Special Interest
Group at the British Society for Rheumawiogy Annual Conference In April 2026.
2. Funding and supporting Psoriatic Arthritis Research
0￿rIng 2025 6rit-PACT has funded one research project which aims to answer research questions relevant to patlents wlth
PSA. This year's Oeepak Jadon Pilot Research Gont awarded to Dr Stephanie ShDop-Worrall Iuniverslty of Manchester)
for the project titled'The Obesity Conundrum.. Childhood obesity and titne to diègnosis and early outcome in Juvenile
P50riatic Arthritis, and she presented a project update to the 8rit-PACT membership at the Annual meeting in October 2025.
A project update bvas 41so presented at this meeting by Dr Steven Zhao (University of Manche5terl who had been awarded
a pilot research grant *n 2024 for his proleci titled'Blood Biomarker for Timely Diagnosis of Psoriatic Arthrib5'.
3. Sharlng patient perspertive on living wlth psoriatic disease.
The patient partner5 continue to share the patient perspective wtth clinicians and other healthcare profe55iona15 and
¢01Saborate var10us oryani5ations to inform research direction. One of the patient members of the Steering Comfflittee
presented at the Annual Meetsng. The paiient group ha5 also advised on Psoriatic Arthritis consensus recommendation5 and
engaged with various activities Including surveys, workshops and assisting with grant applicatlons and other enga9emenV
involvement opportunities.
Financial Re¥iew
Reserves Policy
The board of tfU5tees agree to run the charity with reserves sufficient to meet expenses for approxlmately one year.
Structure Governanco and Managernent
Govern4ng Document
The charlty Is constituted as a Charitable Incorpooted Organisation ICIOI In England & Wales. The governing document of
the charity is the constitution of the CIO as approved by the Charity Cotnmi55ion in England & Wales ICCEWI
The governing document is dated 20 April 2020.
There are no rÉstrSctions in the governing documents on the operation of the Charlty or on its investment powers other than
those imposed by Charity La¥v.
The trus￿e$ arè all individuals.
Tritst¢¢ Seledlon Methods
The Brit-PACT constitution inc(KporatÈs elertions for major executive committee positions. The Executive ComFnittee
Itrusteesl includes rheumatolo9lSts (both consultant5 and trainees), allled health professionals and patient partners. In line
with the constitution of the Charity nominations are sought annually for new executive committÈÈ members as vacancies
become available. Voting Is by a single vote of all member5 and the majority vole is taken as the definltlve resulf. Jn this
calendar year there have been one retirement from the executive committee Ims Clare Allen), two tHÈmbers wÈre re-
elected for a second term (Prof Pauline Ho and Dr Taniè Gudul and one nev4 medical member elected (Dr Carmel Stoberl.
Dr Willliam Tille¢ was also elected as Chair of Brit-PACT and he look ovÈr thi5 role from Dr Nicola Gullick.
Page 2

British Psoriatic Arthritls Consortium
Trustees. Report (continued)
For The Year Ended 31 March 2026
Reference and Admlrtlstratlve Detalls
Trustees
L Coats (resigned 10110120251
N Gullick
P Helliwell
T Gudu
C Allen (resigned 10110120251
PHO
A Kelly
S Mukheriee
RHUM
J Bluett
c stober (appointed IO/1012025}
w rillett
M Jaslm
A Elllot
J Patkham
J Begham
Charlty Numbèr
l 189246
Prlndpal Address
Department l. Wolfsofi Building
Royal Unlted Hospital
Bèth
BAI 3NG
Independent examiner
DR Hi¢ks Chartered Accountants
DR Hick5
Chartered Accountsnts
107 PeTrn Hill Road
Bath
BAI 3RU
Page 3

British Psoriatic Arthritis Consortium
Trustees, Report (continued)
For The Year Ended 31 March 2026
Statement of Trustees. Responslbllltles
The rrustees arè responsible for preparing the Trustees, Report and the financial statements in accordance with applicable law
and United Kingdoffl Accounting Standards {Vnited Kingdom Generally Accepted Accountlng Praciicel-
The law applicable to charltles in England and Wales requlres the trustees to prepare financial statements for each financial
year which give a rrue and falr view of rhe state of affairs of the charity and of the incomlng resources and 3pplicatlon of
resources of the charity for that period. In preparing the financial statements the trustees are required to..
• select suttable accounting policie5 and then apply them con515tentlyi
obSe￿e the methods and principles in the Charity SORP.,
make judgments and accounting esbrnates that are reasonable and prudent. and
prepare the financial statements on the goln9 concern basls unless 5t Is inappropriate to presume that the charlty will
continue in business,
The trustees are responsible for keeping adequate accountlng ￿cO￿lS which dlsclose wlth reasonable accuracy at anyt]me the
financial position of the charity and to enable thetr to ensure that the accounts comply with the Charitie5 kt 2011, the
Charlties {Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for
safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detectson of fraud and
other irregularitie5.
The trustees are responsible for the maintenante and Integrity of the corporate and financial Information Included on the
charity's website. Legislation in the United Kingdom governing the preparation and dissÈmination of fin3n¢ial statements may
differ from legislation In other Jurisdictions,
The trustees, report was approved by the board of trustÈÈs and signed on its behair tjy..
S Mukherjee
Trustee
161LOI2026
Page 4

British Psoriatlc Arthritis Consortium
Independent Examiner's Report to the Trustees of British Psorlatlc Arthrltls Consortium
For The Year Ended 31 March 2026
I report to the trustees on my exomination of the accouftts of British Psoriatic Arthrftis Consortium {the Trust) for the year
ended 31 March 2026.
R•sponslbllltles and Basls of Report
As the charity trustees of the Trust you are ￿sponsible for the preparatlon of the accounts in accordance with the
requlrements of the Charities Act 2011 I-fhe Actl.
I report in ￿SpeCt of my examlnation of the Trust's accounts carded out under section 145 of the 2011 Act and in carrying
out my examination, I have followed the applicable Directions given by the Charity Commission under section 14515}Ibl of
the Act.
Independent Examiner's Statement
I have completed my examination. I confirm that no rnaterial rr+atters have come t(> my attention In Connect[￿ wlth the
Èxamination giving me cause to belleve that in any rnaterial respect..
l. accounDng fftcord5 were not kept in respect of the Trust a5 reouired by section 130 or the Act; or
2. the accounts do not accord with those records,. or
3. the accounts do noi comply ¥Yith the applicable requirements contem1￿ the forrn and contents of accounts set out In
the Charities IAccounts afjd Report51 Regulatlons 2008 other than any requirement that the accounts give a 'true and
falr vlew, whlch Is not a matter cons6dered as part of an independent examinauon.
I have no concerns and have come arross no other matters In connection with the examlnaknon to whlch attentlon should be
drnwn In this report Sn order t(> enable a proper understanding of the accounts to be reached.
(j L£
DR Hicks Chartered Accountants
0410812026
107 Penn Hill Road
Bath
BAI 3RU
Page 5

British Psoriatic Arthritis Consortiurn
Statement of Financial Activities
For The Year Ended 31 March 2026
2026
2025
Unrestrlcted Restrlrted
funds
funds
Total
fund5
Total
fund$
Notes
INCOME AND ENDOWMENTS FROM:
Donations and legacie5
other trading activltles
Investrrents
213
60,000
308
213
142
60,000
308
25,000
246
60.52L
60,521
25.388
EXPEt4DITURE ON:
Raising funds
170.0771
170,0771 165,8151
NET EXPENDITURE
19,5561
19,5561 140,4271
NET MOVEMENT IN FUNDS
19,5561
19,556} 140,4271
RECONCILIATION OF FUNDS-
Total funds brought for*4ard
79,272
52,648
131,920
172,347
TOTAL FUNDS CARRIED FORWARD
li
69,716
52,648
122,364
131.920
The notes on pages 9 to 12 form part or these flnancial starements.
Pa9e 6

Britlsh Psoriatic Arthrltis Consortium
Comparative Statement of Financial Actlvltles
For The Year Ended 31 March 2026
202S
Unrestrlcted Rèstrlct•d
run41$
fund5
Total
funds
14otes
INCOME AND ENDOWMENTS FROM:
OoD3tion$ and legacies
Other tradlng actlvities
Investrnents
142
25.000
246
142
25,000
246
25.388
25,388
EXPENDITURE ON:
Ralslng funds
158.7651
{7,0501 165,8151
NET EXPE14DITURE
133.3771
{7,0501 140,427)
NET MOVEMENT IN FUNDS
RecoNCILIATION OF FUNDS:
Total funds brought Forward
133,3771
{7.0501 140,4271
IL2.649
59.698
172,347
TOTAL FUNDS CARRIED FORWARD
li
79.272
52.648
131,920
The notes on pages 9 to 12 forrn part of these financial 5tatement5.
Page 7

British Psoriatic Arthritis Consortium
Statement of Financlal Position
As At 31 March 2026
2026
2025
Unr*stricted R¢strfctÈd
funds
funds
Total
funds
Total
funds
Not•s
CURRENT ASSETS
Debtors
Cash at bank and in hand
1,985
123,541
1,985
123,541
5,713
128.688
125.526
125,526
134.401
Credltors: Amounts Falllng Due Within One Year
io
{3,1621
13,1621
12.481)
NET CURREt4T ASSETS (UABiLmes)
122,364
122,364
131.920
TOTAL Assrfs LESS CURRENT LIABILITIES
122,364
122,364
131.920
NET AsseTS
122.364
122,364
131.920
FUNDS OF THE CMARirY
Restricted Funds
Unrestricted Fund5
52,648
69,716
52,648
79,272
TOTAL FUNDS
il
122,364
131,920
On behalf of the board
S MukhÈrlee
Trustee
1611012026
The notes on page$ 9 to 12 forn part of these financial statements.
Page 8

British Psoriatic Arthrltls Consortium
Notes to the Financial Statements
For The Year Ended 31 March 2026
l. General Information
Britlsh Psoriatic Arthritis Consortlum is a charitable incorporated organisation registered with the Charlty Commi$5ion,
registered charity number 1189246. The principal address is Departtnent I, Wolfson Building. Royal United Hospitsl, Bath.
BAI 3NG.
2. Accountlng Pollcles
2.1. Basi$ of Pr*parati•n of Flnanelal Statements
The financial ststements have been prepared In actordante with the Charities SORP IFRS 1021 "Accounting and
Reporting by Charitie5'. Statement of Recommended practi￿ applicable to charifi@s preparing their accounts
accordante with the Financsal Reporting Standard applicable In the VK and Republic of Ireland IFRS 1021 (effective I
January 20191" Financial Reportlng Standard 102 'The Financlal Reporting Standard applicable in the UK and Republic
of Ireland" and the Charities Act 2011.
The charlty Is a Public Benefit Entity as deftned by FRS 102.
2.2. Golng Concem Dl$clgsur¢
The trustees have not Identiried any material uncertalntles ￿Tated to events or conditions that may cast 51gnificant
doubt about the chadty's ability to coThtinue as a golng concern.
2.3. Incomln9 Resourcos
Nature of income
Gross income ￿p￿eseThts the value, net of value added tax and discounts, of goods provided tD CUStorner5 and work
carried our in respect of services provided to CU5tomer5.
Categorles of Income
Income Is categorised as income from exthange transactions Icontt7Ct incemel and income from non-exchange
transactions Igiftsl. investment income and other incorne.
Ineome from exchange transactions is received by the charlty for go￿$ or services supplied under cDntoct or where
eDtitlement is sublett to fulfilling performance related condititsns. The incorne the charity receives is approximately
equal in value to the goods or service5 supplied by rhe charity to the purchaser.
Incorne from a non-exchange transaction is where the charity receives value from the donor without proV￿l￿g equal
vèlue In exchallge, and includes donations of moneyi 9oods and servkes freely given without giving equal value in
exchange.
Income retognition
"Income, whether from exchange or rK)n exchange transacUons. Is recognlsed in the ststement of financlal activities
{SOFAI on a receivable basis, when a transaction or other eveft¢ results in an increase in the charity'5 assets or
reductlon In Its liabilities and only when the charity ha5 legal entitlement. the Income is probable and can be measured
reliably.
Dlvldends are accrued when the shareholder's right to receive payrnent is established.
Income subjett to terms and conditions which must be met before the charity Is entlued to the resources is not
recognlsed untll the condition5 have been met.
All Income is accounted for gross. before deducting any related fees or costs..
2.4. Ro$ources Expènded
Recognition of liabilities and expendltu
A liability. and the related expendItu￿, is reeognised when a legal or constructive obligation exlsts as a result of a past
event, and when it is more likely than not that a trdnsfer of economic benefits will be required In settlement. and when
the atnount of the obligatlon can be measured or reliably estimated..
LSabilitie5 arlslng from future funding comrnitments and constructive Obliga￿On5, including perfomance ￿lated grants,
where the tlmlng or rhe amount of the future expenditu￿ required to settle the obligation are uncertain* give rise to a
provision in the accounts, which Is reviewed at the accountin9 year end. The provision is increased to reflect any
in¢r2ases in liabilities. and Is decreased by the utilisatlon of any provlslon within rhe period, and reversed If any
provision is no longer requlred. These movewnents are charged or credited to rhe ￿SpeCtive funds and activities to
which the provision relates.
Page 9

British Psoriatic Arthritis Consortium
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
2.5. Cash and Cash Equi¥alents
Cash cash equivalents are b35ic fin6tTrcial assets and include cash in hand and deposits hdd at call with banks.
other short-terrn highly liquid investments that mature in no more than th￿e months from the date of acqulsition and
are readily convertible to a known amount of cash with insignificaTrt risk of change in val￿, and bank overdrafts.
3. Income from Donations and Legaaes
2026
2025
Unrestrlcted Unrestrfcted
funds
funds
Donations gifts
213
142
4. Income from Other Trading Activltles
2026
202S
Unrestrleted Unrestricted
funds
funds
Spon50r5hips
60.000
25,000
5. Investment Income
2026
2025
Unrestricted Unrestricted
funds
funds
Bank inter￿t recesvable
308
246
6. Analysis of Expenditure
1026
Actlvltles
undertaken
directly
Grant
tundlng of
•ctivitie5
Support
eosts
15ee note 71
Total
Ralsing funds
37.803
25.000
7.274
70.077
2025
Artivitles
undertaken
dirertly
Grant
fundlng of
actlvltles
Support
costs
(see notÈ 71
Total
Ralslng funds
33.805
25.000
7,010
65,815
Page 10

British Psoriatic Arthritis Consortium
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
7. Support Costs
2026
2025
Raising
funds
Raisln9
funds
Employee costs
Premises expenses
General adminlstration
1,014
1.850
4.410
947
1.850
4,213
7,274
7.OLO
8. Indèpendent Examlner's R•muneratlon
2026
2025
Independent examinatlon of the financial statements
1,438
1,398
Debtors
2026
2025
Due wlthin one year
Other debtors
1,985
5,713
10. Credltors: Amounts F•lllng Due Withln One Year
2026
2025
Trade credltors
3.162
2,481
11. Movement In Funds
As at l April
2025
Asat31
Expendlture March 2026
Income
Unrestrirted funds
General..
GenÈral unrestricted fund
Restrlcted funds
79.272
60.521
170,0771
69.716
Sequence Project
52.648
52.648
Total funds
131,920
60.521
170,0771
122.364
As at l April
2024
Asat31
Expendlturè March 2025
rncome
Unrestrlrt4d fvnds
General..
Gener61 unrestrfcted fund
112,649
25,388
158,765)
79,272
.CONTINUED
Pa9e Ll

British Psoriatic Arthritis Consortium
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
Restrlrted fund5
Sequence Project
59,698
17.0501
52.648
Total funds
172,347
25,388
165,8151
131,920
L2. Related Party Dlstlosures
There have been no related party transcations in the ￿pOrting period that requi￿ disctslsu￿.
Page 12

Britlsh Psoriatic Arthritis Consortium
Detailed Statement of Flnancial Artivities
For The Year Ended 31 March 2026
2026
2025
Yotal
funds
Tot#1
funds
INCOME AND eNDOWMENTS FROM:
Donation5 and le9acie8
Donations from individuals
213
142
213
142
other trading art4vltle5
Sponsof5h*ps
60.000
25,000
60.000
25,000
Investments
Bank interest receivable
308
246
308
246
$0,521
25.388
expENDITURE ON:
Ralslng funds
Admlnlstratlon fees
Abstract Award
Patient Partner expenses
c￿rse expenses
Project expenses
50th Anniversiary Meetlrng
Grants to Institutions
Travel and subsistence expense5
Rent
Ccynputer 50ftware, consumables and rnalntenance
Insurance
15,9071
{6801
11051
110,0401
(4,5611
15001
1510)
(9.064}
119,1701
121.07L}
125.0001
{1.014}
{1,850}
1924)
1368)
{911
1237)
{1.438)
12751
19601
11171
125,0(K)}
1947)
(1,850)
1728)
{368)
{2991
12001
11,3981
12201
{9301
1701
Printing, postage and stationery
Telecommunications and data costs
Independent examiner's fees
Subscriptions
Bookkeeping fees
Bank charyes
170.0771
165.8151
170.0771
165,8151
NET EXPENDITURE
19,5561
140.4271
Page L3